EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis

Luc M Berclaz iD, Vindi Jurinovic, Anton Burkhard-Meier, Sultan Abdel-Rahman, Markus Albertsmeier iD, Alexander Klein, Hans Roland Dürr iD, Nina-Sophie Schmidt-Hegemann, Thomas Knösel, Wolfgang G Kunz, Emanuel Stutz, Michael von Bergwelt-Baildon und 2 weitere

Cancer Medicine · 2025-02 · 14 (4)

DOI: 10.1002/cam4.70655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 25.02.2025. Verfasst von Luc M Berclaz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Doxorubicin, Leiomyosarcoma, Antineoplastic Combined Chemotherapy Protocols, Hyperthermia, Induced. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dacarbazine is currently considered the better combination partner for doxorubicin compared to ifosfamide for the treatment of leiomyosarcoma (LMS). Regional hyperthermia (RHT) combined with neoadjuvant chemotherapy has been shown to improve survival in patients with locally advanced high‐risk STS. We sought to evaluate the role of doxorubicin and dacarbazine (AD) versus doxorubicin and ifosfamide (AI) in combination with RHT in patients with LMS.

Methods

Patients with locally advanced high‐grade LMS, including limited metastases, eligible for RHT and first‐line treatment with either AI + RHT or AD + RHT between 2014 and 2022 were retrospectively evaluated. Endpoints were progression‐free survival (PFS) and overall survival (OS). Patients were matched using propensity scores, which were estimated with a logistic regression model accounting for tumor site, presence of metastasis, surgery, and radiotherapy.

Results

A total of 105 patients were included in this study, of which 101 were included in the propensity score‐matched cohort. In the matched cohort, treatment with AD + RHT was associated with a significantly improved PFS (HR 0.32, 95% CI 0.13–0.74, p = 0.0081). Multivariable analysis revealed several significant predictors of PFS, including treatment with AD + RHT (HR 0.42, 95% CI 0.19–0.92, p = 0.031).

Conclusion

Treatment with AD + RHT showed improved PFS and better treatment tolerability compared to AI + RHT. Our results support the use of AD instead of AI for the treatment of patients with LMS in combination with RHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLeiomyosarcomaAntineoplastic Combined Chemotherapy ProtocolsHyperthermia, InducedHumansFemaleMaleMiddle AgedIfosfamidePropensity ScoreRetrospective StudiesAgedAdultDacarbazineCombined Modality Therapy

Stichwörter der Autor:innen

chemotherapyleiomyosarcomaregional hyperthermiasoft tissue sarcoma

Substanzen

DoxorubicinIfosfamideDacarbazine

Autor:innen und Institutionen

  • Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
  • Institute for Medical Information Processing, Biometry, and Epidemiology, University Hospital, LMU Munich, Munich, Germany.
  • Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.
  • Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Luc M Berclaz, Markus Albertsmeier, Hans Roland Dürr

Zitieren

APA

Berclaz, L. M., Jurinovic, V., Burkhard-Meier, A., Abdel-Rahman, S., Albertsmeier, M., Klein, A., Dürr, H. R., Schmidt-Hegemann, N. S., Knösel, T., Kunz, W. G., Stutz, E., von Bergwelt-Baildon, M., Di Gioia, D., & Lindner, L. H. (2025). Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis. Cancer Medicine, 14(4). https://doi.org/10.1002/cam4.70655

Vancouver

Berclaz LM, Jurinovic V, Burkhard-Meier A, Abdel-Rahman S, Albertsmeier M, Klein A, et al. Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis. Cancer Medicine. 2025;14(4). doi:10.1002/cam4.70655

BibTeX
@article{Berclaz2025,
  author = {Berclaz, Luc M and Jurinovic, Vindi and Burkhard-Meier, Anton and Abdel-Rahman, Sultan and Albertsmeier, Markus and Klein, Alexander and Dürr, Hans Roland and Schmidt-Hegemann, Nina-Sophie and Knösel, Thomas and Kunz, Wolfgang G and Stutz, Emanuel and von Bergwelt-Baildon, Michael and Di Gioia, Dorit and Lindner, Lars H},
  title = {Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {4},
  doi = {10.1002/cam4.70655}
}
Kostenlos starten →